CatalystMarker
← board

TARX

Revenue
pre-revenue
Liquidity
—
Runway
—
Shares 1y
—

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: —
  • 2026-06-16F-1/Ashelf_registration
  • 2026-06-08F-1/Ashelf_registration
  • 2026-05-18F-1/Ashelf_registration
  • 2026-05-18FWPoffering
  • 2026-04-21F-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.